New combo therapy aims to reignite immune attack in hard-to-treat liver cancers
NCT ID NCT03259867
First seen Apr 18, 2026 · Last updated May 16, 2026 · Updated 3 times
Summary
This study tests a two-step treatment for people with advanced liver or stomach cancer whose disease got worse after immunotherapy. First, a drug called tirapazamine is injected directly into the liver tumor's blood supply, then patients receive nivolumab, an immunotherapy drug. The goal is to see if this combination can shrink tumors and keep them under control. About 54 adults aged 18 to 80 will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical College of Wisconsin
RECRUITINGMilwaukee, Wisconsin, 53226, United States
Contact Email: •••••@•••••
-
University of California, Irvine
RECRUITINGOrange, California, 92868, United States
Contact Email: •••••@•••••
Contact
Contact
-
University of Oklahoma Health Science Center
RECRUITINGOklahoma City, Oklahoma, 73104, United States
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.